CME credits: 0.75 Valid until: 26-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/patient-case-tailoring-first-line-treatment-for-a-patient-with-metastatic-melanoma-and-impaired-performance-status/24368/ This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim…

CME credits: 0.75 Valid until: 26-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/analyzing-key-data-from-lag-3-combinations-in-the-treatment-of-metastatic-melanoma/24364/ This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metas…

CME credits: 0.75 Valid until: 26-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/future-directions-targeting-lag-3-in-melanoma-treatment/24369/ This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can bene…

CME credits: 0.75 Valid until: 26-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/what-dermatologists-surgeons-need-to-know-adjuvant-treatment-for-resectable-stage-ii-melanoma/24378/ This educational initiative will enhance dermatologists' and surgeons' knowledge, clinical skills, and confidence in recognizing patients who may ben…

CME credits: 0.75 Valid until: 26-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-therapeutic-selection-for-a-patient-with-newly-diagnosed-braf-v600e-mutated-metastatic-melanoma/24365/ This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to iden…

CME credits: 0.75 Valid until: 26-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/first-line-treatment-of-metastatic-melanoma-after-adjuvant-anti-pd-1/24366/ This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma…

CME credits: 0.75 Valid until: 26-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/managing-immunotherapy-related-adverse-events-during-adjuvant-treatment-for-resectable-melanoma/24382/ This educational initiative will enhance dermatologists' and surgeons' knowledge, clinical skills, and confidence in recognizing patients who may b…

CME credits: 0.75 Valid until: 26-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/navigating-adjuvant-ici-treatment-in-stage-ii-melanoma-a-patient-case-presentation/24379/ This educational initiative will enhance dermatologists' and surgeons' knowledge, clinical skills, and confidence in recognizing patients who may benefit from a…

CME credits: 0.75 Valid until: 26-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/what-dermatologists-surgeons-need-to-know-adjuvant-treatment-for-resectable-stage-iiiiv-melanoma/24380/ This educational initiative will enhance dermatologists' and surgeons' knowledge, clinical skills, and confidence in recognizing patients who may …

CME credits: 0.75 Valid until: 26-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-resectable-melanoma-outcomes-through-multidisciplinary-care-and-multimodal-treatment-strategies/24383/ This educational initiative will enhance dermatologists' and surgeons' knowledge, clinical skills, and confidence in recognizing patient…

CME credits: 0.75 Valid until: 26-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/case-consult-adjuvant-therapy-following-localized-treatment-for-stage-iii-melanoma/24381/ This educational initiative will enhance dermatologists' and surgeons' knowledge, clinical skills, and confidence in recognizing patients who may benefit from a…

CME credits: 0.75 Valid until: 26-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/unlocking-synergy-exploring-the-interaction-between-lag-3-and-other-immune-checkpoints/24363/ This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with m…

CME credits: 0.75 Valid until: 26-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/navigating-treatment-related-adverse-effects-in-lag-3-combination-ici-therapy-for-metastatic-melanoma/24367/ This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify …

CME credits: 1.00 Valid until: 25-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/on-the-clinic-floor-addressing-the-most-critical-questions-of-frontline-clinicians-in-multiple-sclerosis-management/16629/ The field of multiple sclerosis (MS) is evolving at a rapid pace from disease modifying therapies (DMTs) to diagnostic/monitori…

CME credits: 1.00 Valid until: 07-11-2024 Claim your CME credit at https://reachmd.com/programs/clinicians-roundtable/idiopathic-pulmonary-fibrosis-the-role-of-radiology-in-accurate-and-timely-diagnosis/18077/ Learn from experts about differentiating idiopathic pulmonary fibrosis (IPF) from other interstitial lung diseases and the role of radiology…

CME credits: 0.25 Valid until: 12-11-2024 Claim your CME credit at https://reachmd.com/programs/cme/experts-on-the-ground-data-updates-on-emerging-therapies-for-igan/24045/ Expert Nephrologist Richard Lafayette, MD, FACP, gives an overview of top abstracts from Kidney Week 2023 and updates on emerging therapies for IgAN. =…

CME credits: 1.00 Valid until: 04-06-2024 Claim your CME credit at https://reachmd.com/programs/cme/experts-on-call-connecting-specialists-and-pcps-to-improve-patient-centered-obesity-management/24044/ Obesity experts review obesity management strategies and provide insight on best practices for implementation in a primary care setting. =…

CME credits: 0.25 Valid until: 24-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/multidisciplinary-approach-to-diagnosing-and-managing-indolent-systemic-mastocytosis-the-changing-landscape/18090/ Patients with indolent systemic mastocytosis frequently report a symptom burden disproportionate to measurable disease burden. Anti-med…

CME credits: 0.50 Valid until: 24-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/managing-indolent-systemic-mastocytosis-a-multidisciplinary-case-review/18089/ New tyrosine kinase inhibitor (TKI) treatment options can significantly reduce symptom burden in patients with moderate to severe indolent systemic mastocytosis (ISM). Stu…

CME credits: 1.00 Valid until: 23-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-multiple-faces-of-attrv-pn/24134/ Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the …

CME credits: 1.00 Valid until: 23-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/attrv-pn-a-family-affair/24138/ Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Explore the comple…

CME credits: 1.00 Valid until: 23-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/shhgene-silencing-therapies-for-attrv-pn/24137/ Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Ex…

CME credits: 1.00 Valid until: 23-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/raising-the-red-flag-whats-your-index-of-suspicion-for-attrv-pn/24135/ Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectu…

CME credits: 1.00 Valid until: 23-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/attrv-pn-a-complicated-disease-with-a-poor-prognosis/24133/ Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and in…

CME credits: 1.00 Valid until: 23-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/diagnosing-attrv-pn-whats-in-your-toolbox/24136/ Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. E…

CME credits: 1.00 Valid until: 23-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/advancing-the-treatment-of-attrv-pn-whats-in-the-pipeline/24139/ Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, a…

CME credits: 1.00 Valid until: 23-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/attr-amyloidosis-familial-vs-wild-type/24132/ Deepen your understanding of hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with this comprehensive CME series! Gain valuable insights from patient cases, expert lectures, and interviews. Expl…